NANOFH — Nanoform Finland Oyj Share News
0.000.00%
Last trade - 00:00- €63.63m
- €51.03m
- €3.55m
Brief: Nanoform Q2 EBITDA EUR -3 Million
Brief: Nanoform Receives Positive Feedback From UK Mhra Scientific Advice Meeting
Finland's Nanoform Q1 revenue rises 45%, EBITDA loss narrows
Brief: Nanoform Finland Targets Cash Burn Below EUR 10 Mln For 2026
Brief: Nanoform Signs Agreement With U.S. Biopharma Company
Brief: Nanoform Finland Q4 EBITDA Loss EUR 1.1 Mln
Brief: Nanoform's Nanotrastuzumab Matches Performance Of Herceptin Hylecta
Brief: Nanoform Finland To Lay Off 49 Employees
Brief: Nanoform Starts Change Negotiations As Part Of New 2030 Midterm Business Targets
Brief: Nanoform Announces New Midterm Business Targets For 2030
Brief: Nanoform Finland Q3 Revenue Down At EUR 0.7 Million
Brief: Nanoform Received License From Fimea For APIs In Finland
Brief: Nanoform Finland Announces Partnership With Revio Therapeutics
Brief: Nanoform Signs Distributor Agreement With A&Ls In South Korea
Brief: Nanoform Q2 EBITDA EUR -5.1 Million
Brief: Nanoform Finland Secures EUR 5 Mln R&D Loan
Brief: Nanoform Finland Starts Pivotal Bioequivalence Studies Of Nanoenzalutamide
Brief: Nanoform Partners With Healthcare Investors To Develop, Commercialise Nanoencorafenib
Brief: Nanoform Q1 EBITDA Loss EUR 4.9 Mln